News | September 24, 2025
Briefs: Relonchem, Patel Chem Specialities and J & H Pharma Consultants
Relonchem receives marketing authorization for Moxonidine tablets
Relonchem receives marketing authorization for Moxonidine tablets
The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
It is intended for contrast enhancement in MRI scans
Subscribe To Our Newsletter & Stay Updated
